“Caraway is developing oral small molecule therapeutics that enhance lysosomal function to accelerate clearance of toxic materials, such as proteins, oligomers and lipids, that accumulate in many genetically defined neurodegenerative and rare diseases,” said Williams.
“Caraway is developing oral small molecule therapeutics that enhance lysosomal function to accelerate clearance of toxic materials, such as proteins, oligomers and lipids, that accumulate in many genetically defined neurodegenerative and rare diseases,” said Williams. “I look forward to providing updates on our TRPML1 and pipeline programs at the Oppenheimer conference.”
About Caraway Therapeutics
Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating lysosomal function. Caraway is utilizing its unique product engine to develop proprietary insights into lysosomal function and small molecule ion channel modulation and advance a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.
Caraway is based in Cambridge, MA. For more information, please visit www.carawaytx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005203/en/
Media:
MacDougall
Kari Watson or Nicholas Chang
(781) 235-3060
kwatson@macbiocom.com or nchang@macbiocom.com
Source: Caraway Therapeutics
View this news release online at:
http://www.businesswire.com/news/home/20220308005203/en
